Cochlear (ASX:COH) Cut Its Dividend After Full Year Results, Is The Rebound Already Priced In?

Cochlear (ASX:COH) came into focus on 17 August 2026 after issuing full year 2026 results, cutting its ordinary dividend and guiding to low single digit constant currency sales revenue growth for fiscal 2027.

Cochlear's recent update comes after a sharp reset in sentiment, with the share price at A$137.71, a 30 day share price return of 20.27% and a 90 day share price return of 41.39%. However, the year to date share price return is down 47.24% and the 1 year total shareholder return is down 53.44%, suggesting that recent momentum has picked up following the earnings, dividend and guidance announcement, yet long term holders are still sitting on sizeable losses.

Compare Cochlear's sharp sentiment reset with other healthcare stocks facing earnings pressure by scanning our hand picked list of solid balance sheet and fundamentals (20 results) that combine resilience with fundamental strength.

After a sharp rebound in Cochlear on tough earnings, a lower dividend and cautious sales guidance, the key issue now is simple. Is the recent share price surge the bulk of the recovery, or is material upside still ahead on valuation grounds?

Most Popular Narrative: 96.7% Overvalued

Cochlear's last close at A$137.71 sits well above the A$70 fair value in the most followed narrative. This frames the recent rebound as a reset rather than a clean slate.

There has also been a dramatic recent decline in the company’s share price, which may suggest a potential buying opportunity. The sell-off followed an earnings downgrade, with management citing weaker-than-expected demand, hospital constraints, softer referral rates, and geopolitical risks.

Read the complete narrative. Read the complete narrative.

Want to understand why this narrative still points to a lower fair value for Cochlear despite forecast profit growth and heavy R&D investment? According to Robbo, the valuation hinges on how elective surgery demand, margins and competitive technology threats reshape cash flows over time. Curious which assumptions pull the fair value all the way down to A$70 while current earnings forecasts remain upbeat?

Result: Fair Value of A$70 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Cochlear could challenge this overvaluation view if elective surgery volumes recover faster than expected, or if new hearing technologies strengthen its competitive edge.

Find out about the key risks to this Cochlear narrative.

Another View on Cochlear's Valuation

While the most followed narrative points to Cochlear trading well above an A$70 fair value, our DCF model tells a different story. At A$137.71, Cochlear is assessed as trading about 40% below an estimated future cash flow value of A$230.61. That raises a simple question: which set of assumptions do you trust more over the long run?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Cochlear for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 13 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this Cochlear update leaves you torn between caution and optimism, take action while the details are fresh and weigh up the trade off yourself. To see the specific issues investors are focused on, review the 2 key rewards and 2 important warning signs

Looking for more Cochlear investment ideas?

Before moving on from Cochlear, widen your watchlist with fresh stock ideas that fit your goals, so you are not relying on a single opportunity.

Use the Simply Wall Street Screener to explore ideas that match how you like to invest.

• Target potential bargains supported by solid fundamentals through a curated list of 13 high quality undervalued stocks.
• Build an income focused watchlist by reviewing a focused group of 6 dividend fortresses that combine yield with resilience.
• Protect your downside by filtering for 10 resilient stocks with low risk scores that score well on financial strength and stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com